Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of XY0206 in relapsed/refractory FLT3-ITD-mutated acute myeloid leukemia
CTR20231024Phase 3Active
- Sponsor
- Yiling Pharmaceutical
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of XY0206 in acute myeloid leukemia (AML), sponsored by Yiling Pharmaceutical. Started Jul 2023; status: active.
02
Drugs
XY0206
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on CTR20231024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231024.